Widespread gene transduction to the central nervous system by adenovirus in utero:: implication for prenatal gene therapy to brain involvement of lysosomal storage disease

Background In some lysosomal storage diseases, considerable alterations of the central nervous system (CNS) occur prior to birth and neurodegeneration progresses rapidly soon after birth causing early death in patients. No effective treatment is available after birth. Treatment may need to be initiated before birth to prevent the onset or progression of neurological changes and thereby irreversible brain damage. The aim of this study is to investigate the feasibility and effectiveness of brain-directed prenatal gene therapy for lysosomal storage diseases. Methods Recombinant adenovirus encoding the 1acZ gene was injected into the lateral ventricles of mouse embryos and the pattern of gene transduction to the CNS was investigated. In the therapeutic experiment, adenovirus expressing beta-glucuronidase was injected into the cerebral ventricles of the embryos of mucopolysaccharidosis VII mice and the therapeutic effects on the brain were evaluated. Results Injection of adenoviral vectors to the cerebral ventricles of mouse embryos led to widespread gene transduction. throughout the brain and the spinal cord and transgene expression persisted over 10 months in those surviving the procedure. The prenatal transduction of the therapeutic gene to the brain of the mucopolysaccharidosis VII mouse efficiently prevented lysosomal storage in most brain cells before birth until 4 months after birth. Conclusions Brain-directed in utero gene therapy through an intraventricular route would be an effective strategy to treat some lysosomal storage diseases with early and severe CNS alterations. Copyright (C) 2004 John Wiley Sons, Ltd.